These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 16680870)

  • 41. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol.
    Pan LP; Wijnant P; De Vriendt C; Rosseel MT; Belpaire FM
    Br J Clin Pharmacol; 1997 Dec; 44(6):557-64. PubMed ID: 9431831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The inhibitory effect of amiodarone and desethylamiodarone on dextromethorphan O-demethylation in human and rat liver microsomes.
    Jaruratanasirikul S; Hortiwakul R
    J Pharm Pharmacol; 1994 Nov; 46(11):933-5. PubMed ID: 7897605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes.
    Yoshii K; Kobayashi K; Tsumuji M; Tani M; Shimada N; Chiba K
    Life Sci; 2000; 67(2):175-84. PubMed ID: 10901285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes.
    Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK
    Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine.
    Wang RW; Liu L; Cheng H
    Drug Metab Dispos; 1996 Jul; 24(7):786-91. PubMed ID: 8818577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
    Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
    Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan.
    Rodrigues AD; Kukulka MJ; Surber BW; Thomas SB; Uchic JT; Rotert GA; Michel G; Thome-Kromer B; Machinist JM
    Anal Biochem; 1994 Jun; 219(2):309-20. PubMed ID: 8080088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
    Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
    Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
    Bourrié M; Meunier V; Berger Y; Fabre G
    J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes.
    Zhou X; Wang Y; Or PM; Wan DC; Kwan YW; Yeung JH
    Phytomedicine; 2012 May; 19(7):648-57. PubMed ID: 22541637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vivo administration of H2 blockers, cimetidine and ranitidine, reduced the contents of the cytochrome P450IID (CYP2D) subfamily and their activities in rat liver microsomes.
    Orishiki M; Matsuo Y; Nishioka M; Ichikawa Y
    Int J Biochem; 1994 Jun; 26(6):751-8. PubMed ID: 8063004
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.
    Jacqz-Aigrain E; Funck-Brentano C; Cresteil T
    Pharmacogenetics; 1993 Aug; 3(4):197-204. PubMed ID: 8220439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of impurities on IC50 values of P450 inhibitors.
    Huang Z
    Drug Metab Lett; 2011 Aug; 5(3):156-62. PubMed ID: 21722088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide.
    Leemann T; Bonnabry P; Dayer P
    Life Sci; 1994; 54(14):951-6. PubMed ID: 8139385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.
    Johnson JA; Herring VL; Wolfe MS; Relling MV
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1099-105. PubMed ID: 10945865
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
    Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
    Draper AJ; Madan A; Parkinson A
    Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gliclazide hydroxylation by rat liver microsomes.
    Rieutord A; Stupans I; Shenfield GM; Gross AS
    Xenobiotica; 1995 Dec; 25(12):1345-54. PubMed ID: 8719909
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro.
    Zhang W; Ramamoorthy Y; Tyndale RF; Sellers EM
    Drug Metab Dispos; 2003 Jun; 31(6):768-72. PubMed ID: 12756210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes.
    Storelli F; Desmeules J; Daali Y
    Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):170-180. PubMed ID: 30192434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.